Graham G. Walmsley 4

What Happened

• Graham G. Walmsley, a director of Olema Pharmaceuticals (OLMA), received a grant of derivative securities covering 29,500 shares on 2026-06-18. The Form 4 reports an acquisition (code A) of 29,500 shares at a reported price of $0.00 (derivative).
• This is a compensation award (an option) rather than an open-market purchase or sale; no proceeds were paid and no shares were sold.

Key Details

• Transaction date: 2026-06-18; Filing date: 2026-06-23 (filed 5 days after the transaction; appears later than the usual 2-business-day Form 4 window).
• Reported amount: 29,500 shares; reported price/exercise: $0.00; total reported cash value: $0 (as shown on the Form 4).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Footnote: the shares subject to the option vest in 12 equal monthly installments beginning June 18, 2026, contingent on continuous service. If not fully vested sooner, they vest in full on the issuer’s next annual meeting of stockholders (subject to continued service).
• Transaction code: A (award/grant of derivative securities).

Context

• This is a typical equity-compensation grant to a director; it does not involve an immediate market purchase or sale of stock and therefore is not a direct buy/sell signal.
• The award vests over time (monthly) and may fully vest at the next annual meeting if not vested earlier, so the economic interest is subject to future service-based vesting and not immediately tradable.